Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides and Orbicular enter into a strategic partnership to jointly develop a range of nasal sprays03-05-2023
03-05-2023
Strides Pharma Science Ltd - 532531 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Strides Pharma Science Ltd 2 CIN NO. L24230MH1990PLC057062 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY2022-23, 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Manjula RamamurthyDesignation :-Company Secretary Name of the Chief Financial Officer :- Badree Komandur Designation : -Executive Director Finance and Group CFO Date: 28/04/202328-04-2023
Strides Pharma Science Ltd - 532531 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyStrides Pharma Science Ltd 2CIN NO.L24230MH1990PLC057062 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manjula Ramamurthy Designation: Company Secretary EmailId: manjula.r@strides.com Name of the Chief Financial Officer: Badree Komandur Designation: Executive Director Finance and Group CFO EmailId: badree.komandur@strides.com Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-04-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Vijay Jayantilal Shah24-04-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Valerian S DSouza/ Olivia Clara Dsouza17-04-2023
Strides Pharma Science Ltd - 532531 - Certificate Pursuant To Regulation 40 (9) Of SEBI (LODR) Regulations, 2015
Pursuant to Regulation 40 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Compliance Certificate for the year ended on March 31, 2023 duly certified by the Practicing Company Secretary.14-04-2023
Strides Pharma Science Ltd - 532531 - Compliance Certificate For FY 2023
Compliance Certificate for FY 202307-04-2023
Strides Pharma Science Ltd - 532531 - Voting Results Of Postal Ballot Pursuant To Regulation 44 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 And Scrutinizer'S Report.
Voting Results of Postal Ballot pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer's Report.23-03-2023
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd23-03-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201520-03-2023